Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 19/20 | 1.00 |
| ▸ | ESR1 | P03372 | 6/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28158911 | 1.00 | ESR2 (1.00) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL433755 | 0.92 | ESR2 (1.00) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| Ethylene SCHEMBL8152920 | 0.89 | ESR2 (0.92) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL3964037 | 0.85 | ESR2 (0.74) | ESR2ESR1CYP3A4CYP2C9CYP2D6 | |
| SCHEMBL14403055 | 0.82 | ESR2 (0.78) | ESR2 | |
| SCHEMBL28137635 | 0.81 | ESR2 (0.69) | ESR2CYP2C9 | |
| SCHEMBL2150282 | 0.81 | ESR2 (0.78) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL2150278 | 0.81 | ESR2 (0.78) | ESR2ESR1CYP3A4CYP2C9 | |
| SCHEMBL1074881 | 0.81 | ESR2 (0.68) | ESR2 | |
| SCHEMBL2094843 | 0.80 | ESR2 (0.76) | ESR2ESR1CYP3A4CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570077-B2 | Substituted (4'-hydroxyphenyl)cyclohexane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform | MARQUETTE UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20160340279-A1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOAKLKANE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM | MARQUETTE UNIVERSITY (US) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340279-A1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOAKLKANE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM | ESR2, GPER1, ESRRG | ESR2 1/4885ESR1 4/4885CYP3A4 558/4885 |
| US-10570077-B2 | Substituted (4'-hydroxyphenyl)cyclohexane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform | ESR2, GPER1, ESR1 | ESR2 1/4885ESR1 3/4885CYP3A4 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.